Lung cancer: Potential targets for immunotherapy

The Lancet Respiratory Medicine

Volumn 1, Issue 7, 2013, Pages 551-563

  Tartour, Eric ^a,b   Zitvogel, Laurence ^c,d  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; ANTINEOPLASTIC AGENT; AZACITIDINE; BELAGENPUMATUCEL L; BMS 936559; CANCER VACCINE; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; EMEPEPIMUT S; ENTINOSTAT; IPILIMUMAB; LACTOFERRIN; MELANOMA ANTIGEN 3; MONOCLONAL ANTIBODY; MONTANIDE ISA 51; MUCIN 1; NIVOLUMAB; NY ESO 1 ANTIGEN; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; RACOTUMOMAB; RECOMBINANT EPIDERMAL GROWTH FACTOR; TALACTOFERRIN; TELOMERASE; TERTOMOTIDE; TG 4010; UNCLASSIFIED DRUG; UNINDEXED DRUG; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; TUMOR ANTIGEN;

ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTINUOUS INFUSION; DRUG DOSE COMPARISON; DRUG RESEARCH; ENTEROCOLITIS; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; UNSPECIFIED SIDE EFFECT; CARCINOMA, NON-SMALL-CELL LUNG; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; PROCEDURES; TUMOR MICROENVIRONMENT;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84883450101     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70159-0     Document Type: Review

References (125)

1. Witschi H A short history of lung cancer. Toxicol Sci 2001, 64:4-6.
2. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008, 26:3552-3559.
3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
4. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
5. Coussens LM, Zitvogel L, Palucka AK Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013, 339:286-291.
6. Bradbury PA, Shepherd FA Immunotherapy for lung cancer. J Thorac Oncol 2008, 3:164-170.
7. Jimenez C, Manrique A, Marques E, et al. Incidence and risk factors for the development of lung tumors after liver transplantation. Transpl Int 2007, 20:57-63.
8. Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011, 306:1891-1901.
9. Prado-Garcia H, Romero-Garcia S, Aguilar-Cazares D, Meneses-Flores M, Lopez-Gonzalez JS Tumor-induced CD8+ T-cell dysfunction in lung cancer patients. Clin Dev Immunol 2012, 2012:741741.
10. Wang J, Zou ZH, Xia HL, He JX, Zhong NS, Tao AL Strengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials. PLoS One 2012, 7:e32695.
11. Mami-Chouaib F, Echchakir H, Dorothee G, Vergnon I, Chouaib S Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen. Immunol Rev 2002, 188:114-121.
12. Tsuji T, Altorki NK, Ritter G, Old LJ, Gnjatic S Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination. J Immunol 2009, 183:4800-4808.
13. Kawai O, Ishii G, Kubota K, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008, 113:1387-1395.
14. Suzuki K, Kadota K, Sima CS, et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol 2013, 31:490-498.
15. Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008, 26:4410-4417.
16. Grunwald C, Koslowski M, Arsiray T, et al. Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. Int J Cancer 2006, 118:2522-2528.
17. Ichiki Y, Takenoyama M, Mizukami M, et al. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol 2004, 172:4844-4850.
18. Hogan KT, Eisinger DP, Cupp SB, et al. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res 1998, 58:5144-5150.
19. Karanikas V, Colau D, Baurain JF, et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001, 61:3718-3724.
20. Echchakir H, Mami-Chouaib F, Vergnon I, et al. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001, 61:4078-4083.
21. Takenoyama M, Baurain JF, Yasuda M, et al. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer 2006, 118:1992-1997.
22. Lai CL, Tsai CM, Tsai TT, et al. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin Cancer Res 1998, 4:3025-3030.
23. Rosenfeld MR, Malats N, Schramm L, et al. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst 1997, 89:381-385.
24. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150:1107-1120.
25. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012, 150:1121-1134.
26. Remark R, Alifano M, Cremer I, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 2013, published online June 19. 10.1158/1078-0432.CCR-12-3847.
27. O'Callaghan DS, O'Donnell D, O'Connell F, O'Byrne KJ The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol 2010, 5:2024-2036.
28. Cramer DW, Finn OJ Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol 2011, 23:265-271.
29. Badoual C, Sandoval F, Pere H, et al. Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck 2010, 32:946-958.
30. Badoual C, Bouchaud G, Agueznay Nel H, et al. The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 2008, 68:3907-3914.
31. Zhu YM, Webster SJ, Flower D, Woll PJ Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer 2004, 91:1970-1976.
32. Yamaji H, Iizasa T, Koh E, et al. Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol Immunother 2004, 53:786-792.
33. Li CW, Xia W, Huo L, et al. Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res 2012, 72:1290-1300.
34. Chen X, Wan J, Liu J, et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010, 69:348-354.
35. Sorrentino C, Di Carlo E Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 2009, 180:769-779.
36. Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010, 5:585-590.
37. Srivastava MK, Andersson A, Zhu L, et al. Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy 2012, 4:291-304.
38. So T, Takenoyama M, Mizukami M, et al. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res 2005, 65:5945-5952.
39. Salmon H, Franciszkiewicz K, Damotte D, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 2012, 122:899-910.
40. Le Maux Chansac B, Moretta A, Vergnon I, et al. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol 2005, 175:5790-5798.
41. Platonova S, Cherfils-Vicini J, Damotte D, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 2011, 71:5412-5422.
42. Schreiber RD, Old LJ, Smyth MJ Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
43. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
44. Tucker ZC, Laguna BA, Moon E, Singhal S Adjuvant immunotherapy for non-small cell lung cancer. Cancer Treat Rev 2012, 38:650-661.
45. Thomas A, Hassan R Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 2012, 13:e301-e310.
46. Galili U Conversion of tumors into autologous vaccines by intratumoral injection of alpha-Gal glycolipids that induce anti-Gal/alpha-Gal epitope interaction. Clin Dev Immunol 2011, 2011:134020.
47. Brahmer JR Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol 2013, 31:1021-1028.
48. Escudier B, Dorval T, Chaput N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med 2005, 3:10.
49. Viaud S, Thery C, Ploix S, et al. Dendritic cell-derived exosomes for cancer immunotherapy: what's next?. Cancer Res 2010, 70:1281-1285.
50. Zitvogel L, Regnault A, Lozier A, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998, 4:594-600.
51. Thery C, Duban L, Segura E, Veron P, Lantz O, Amigorena S Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002, 3:1156-1162.
52. Morse MA, Garst J, Osada T, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005, 3:9.
53. Viaud S, Terme M, Flament C, et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One 2009, 4:e4942.
54. Viaud S, Ploix S, Lapierre V, et al. Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-γ. J Immunother 2011, 34:65-75.
55. Kroemer G, Zitvogel L, Galluzzi L Victories and deceptions in tumor immunology: Stimuvax. Oncoimmunology 2013, 2:e23687.
56. Vansteenkiste J, Zielinski M, Dahabreh I, et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2008, 26(suppl 15):7501.
57. Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008, 26:1452-1458.
58. Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011, 12:1125-1133.
59. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of Belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small cell lung cancer. J Clin Oncol 2006, 24:4721-4730.
60. Fakhrai H, Tong A, Nemunaitis J, Shawler DL Correlation of immune response and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer. Proc Am Soc Clin Oncol 2009, 27(suppl 15). abstr 3013.
61. Nemunaitis J, Nemunaitis M, Senzer N, et al. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 2009, 16:620-624.
62. Kruit W, Suciu S, Dreno B, et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label phase II study of the EORTC Melanoma Group (16032-18031). Proc Am Soc Clin Oncol 2008, 26(suppl 15). abstr 9065.
63. Brunsvig PF, Kyte JA, Kersten C, et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 2011, 17:6847-6857.
64. Benavides LC, Sears AK, Gates JD, et al. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. Expert Rev Vaccines 2011, 10:201-210.
65. Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007, 57:365-372.
66. Pere H, Montier Y, Bayry J, et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011, 118:4853-4862.
67. van Duikeren S, Fransen MF, Redeker A, et al. Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. J Immunol 2012, 189:3397-3403.
68. Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol 2008, 3:735-744.
69. Bolonaki I, Kotsakis A, Papadimitraki E, et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 2007, 25:2727-2734.
70. Barve M, Bender J, Senzer N, et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 2008, 26:4418-4425.
71. Nemunaitis J, Senzer N, Olivares J, et al. Immune response and survival of refractory cancer patients who received TGF-beta2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine. Gene Ther 2013, published online March 7. 10.1038/gt.2013.9.
72. He W, Liu Q, Wang L, Chen W, Li N, Cao X TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007, 44:2850-2859.
73. Cherfils-Vicini J, Platonova S, Gillard M, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010, 120:1285-1297.
74. Parikh PM, Vaid A, Advani SH, et al. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol 2011, 29:4129-4136.
75. Sznol M, Chen L Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013, 19:1021-1034.
76. Zhang Y, Huang S, Gong D, Qin Y, Shen Q Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010, 7:389-395.
77. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
78. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012, 30:2046-2054.
79. Kroemer G, Galluzzi L, Kepp O, Zitvogel L Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013, 31:51-72.
80. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
81. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
82. Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013, 19:462-468.
83. Brahmer JR, Horn L, Antonia SJ, et al. Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2013, 31. abstr 8030.
84. Spigel DR, Gettinger SN, Horn L, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2013, 31. abstr 8008.
85. Wrangle J, Wang W, Koch A, et al. Epigenetic therapy and sensitization of lung cancer to immunotherapy. American Association for Cancer Research Annual Meeting; Washington DC, USA; April 6-10, 2013. Abstract 4619.
86. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059.
87. Delahaye NF, Rusakiewicz S, Martins I, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011, 17:700-707.
88. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012, 11:215-233.
89. Menger L, Vacchelli E, Adjemian S, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 2012, 4:143ra99. 10.1126/scitranslmed.3003807.
90. Martins I, Kepp O, Schlemmer F, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011, 30:1147-1158.
91. Michaud M, Martins I, Sukkurwala AQ, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334:1573-1577.
92. Ma Y, Adjemian S, Mattarollo SR, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013, 38:729-741.
93. Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010, 70:3052-3061.
94. Mitchem JB, Brennan DJ, Knolhoff BL, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 2013, 73:1128-1141.
95. Mole RH Whole body irradiation; radiobiology or medicine?. Br J Radiol 1953, 26:234-241.
96. Demaria S, Bhardwaj N, McBride WH, Formenti SC Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005, 63:655-666.
97. Cummings RJ, Mitra S, Foster TH, Lord EM Migration of skin dendritic cells in response to ionizing radiation exposure. Radiat Res 2009, 171:687-697.
98. Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013, 86:343-349.
99. Formenti SC, Demaria S Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013, 105:256-265.
100. Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005, 11:728-734.
101. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15:5379-5388.
102. Verbrugge I, Hagekyriakou J, Sharp LL, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012, 72:3163-3174.
103. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:925-931.
104. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 2013, 85:293-295.
105. Seung SK, Curti BD, Crittenden M, et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and immunological responses. Sci Transl Med 2012, 4:137ra74.
106. Brody JD, Ai WZ, Czerwinski DK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010, 28:4324-4332.
107. Kim YH, Gratzinger D, Harrison C, et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 2012, 119:355-363.
108. Luo Q, Gu Y, Zheng W, et al. Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway. Toxicol Appl Pharmacol 2011, 251:130-136.
109. Yamamoto N, Honma M, Suzuki H Off-target serine/threonine kinase 10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders. Mol Pharmacol 2011, 80:466-475.
110. Kanazawa S, Yamaguchi K, Kinoshita Y, Komiyama Y, Muramatsu M, Nomura S Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib. J Cancer Res Clin Oncol 2006, 132:719-725.
111. Adotevi O, Pere H, Ravel P, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010, 33:991-998.
112. Tartour E, Pere H, Maillere B, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011, 30:83-95.
113. Terme M, Pernot S, Marcheteau E, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013, 73:539-549.
114. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008, 14:6674-6682.
115. Terme M, Colussi O, Marcheteau E, Tanchot C, Tartour E, Taieb J Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol 2012, 2012:492920.
116. Vokes EE, Salgia R, Karrison TG Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol 2013, 24:6-9.
117. Sandoval F, Terme M, Nizard M, et al. Mucosal imprinting of vaccine-induced CD8+ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013, 5:172ra20. 10.1126/scitranslmed.3004888.
118. Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012, 72:1081-1091.
119. Kroemer G, Zitvogel L Can the exome and the immunome converge on the design of efficient cancer vaccines?. Oncoimmunology 2012, 1:579-580.
120. Gerdes CA, Nicolini VG, Herter S, et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res 2013, 19:1126-1138.
121. Ait-Tahar K, Barnardo MC, Pulford K CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma. Cancer Res 2007, 67:1898-1901.
122. Casey SC, Bellovin DI, Felsher DW Noncanonical roles of the immune system in eliciting oncogene addiction. Curr Opin Immunol 2013, 25:246-258.
123. Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011, 17:1094-1100.
124. Rakhra K, Bachireddy P, Zabuawala T, et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010, 18:485-498.
125. Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013, 19:747-752.